Sign In
21 Apr 2022 07:00
Belluscura plc
("Belluscura" or the "Company" or "Group")
Senior Management Appointment
LONDON, U.K. AND PLANO, TX, U.S. (21 April 2022). Belluscura plc (AIM: BELL), a leading medical device developer focused on lightweight and portable oxygen enrichment technology, announces that Brian Brown has joined the Company as Vice President of Engineering.
Brian has over 25 years of experience in commercializing break-through new products in hardware, software, and service delivery industries. In his career, Brian built a start-up firm into a world leading supplier of diagnostic imaging medical devices holding the titles of President and Chief Innovation Officer. In addition to degrees in electrical engineering, he is a registered professional engineer and is the author of 17 US patents.
Robert Rauker, Chief Executive Officer, Belluscura plc, commented: "We look forward to leveraging Brian's background in new product commercialization. His knowledge in building a start-up medical device firm will add to our experienced management team. We're excited to have Brian on board."
Brian Brown commented: "It's exciting to be part of a very talented Belluscura team. I look forward to helping Belluscura launch its breakthrough new technologies and change the face of patient care."
For further information please contact:
Belluscura plc | www.belluscura.com |
Robert Rauker, Chief Executive Officer | via Walbrook PR |
Anthony Dyer, Chief Financial Officer | |
SPARK Advisory Partners Limited (NOMAD) | Tel: +44 (0)20 3368 3550 |
Neil Baldwin | |
Dowgate Capital Limited (Broker) | Tel: +44 (0)20 3903 7715 |
James Serjeant / Nicholas Chambers | |
Walbrook PR Ltd (Media & Investor Relations) | Tel: +44 (0)20 7933 8780 or belluscura@walbrookpr.com |
Paul McManus / Sam Allen | Mob: +44 (0)7980 541 893 / +44 (0)7502 558 258 |
About Belluscura plc (www.belluscura.com)
Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations.
About Reach announcements
Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases such as marketing messages, corporate and product information into the public domain. An RNS Regulatory announcement is required to be notified under the AIM Rules for Companies.
Follow the stocks
